EMA panel grants positive opinion for Remdesivir use in COVID patients with severe renal impairment, including those on dialysis: Gilead Sciences Ruchika Sharma28 May 2023 6:30 AM GMTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences, Arcus Biosciences expand partnership to include research programs in inflammation Ruchika Sharma16 May 2023 5:00 AM GMTFoster City: Gilead Sciences, Inc. and Arcus Biosciences, Inc. have announced that the companies have expanded the previously announced research...
Gilead Sciences acquires all outstanding shares of XinThera Ruchika Sharma13 May 2023 4:30 AM GMTFoster City: Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San...
Gilead Sciences gets EMA panel postive opinion recommending full marketing nod of Hepcludex for HDV Ruchika Sharma5 May 2023 8:00 AM GMTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences, US square off in billion-dollar HIV drug patent trial Ruchika Sharma2 May 2023 10:16 AM GMTThe USFDA approved Gilead's Truvada for HIV prevention in 2012 and approved its related drug Descovy for the same purpose in 2019.
Gilead Sciences exercises option to license Nurix's investigational targeted protein degrader molecule NX-0479 Ruchika Sharma21 March 2023 11:52 AM GMTFoster City: Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein...
Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer Ruchika Sharma4 Feb 2023 6:07 AM GMTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
EMA validates marketing authorization application for Trodelvy for Pre-treated HR+/HER2- Metastatic Breast Cancer: Gilead Sciences Ruchika Sharma5 Jan 2023 11:00 AM GMTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences to acquire all remaining rights to potential first-in-class immunotherapy GS-1811 from Jounce Therapeutics Ruchika Sharma28 Dec 2022 7:00 AM GMTJounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and...
Gilead Sciences bags USFDA nod for Sunlenca to treat HIV-1 infection Ruchika Sharma23 Dec 2022 10:39 AM GMTLenacapavir is a breakthrough innovation with the potential to be a preferred and versatile foundational long-acting agent due to its therapeutic...
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 9:00 AM GMTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Shilpa Medicare gets USFDA nod for Tenofovir Alafenamide Tablets Ruchika Sharma19 Sep 2022 5:55 AM GMTNew Delhi: Shilpa Medicare has recently announced that the Company has received U.S Food and Drug Administration (USFDA) tentative approval for...
